ES2300141T3 - Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson. - Google Patents

Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson. Download PDF

Info

Publication number
ES2300141T3
ES2300141T3 ES99915809T ES99915809T ES2300141T3 ES 2300141 T3 ES2300141 T3 ES 2300141T3 ES 99915809 T ES99915809 T ES 99915809T ES 99915809 T ES99915809 T ES 99915809T ES 2300141 T3 ES2300141 T3 ES 2300141T3
Authority
ES
Spain
Prior art keywords
dopa
riluzole
weight
treatment
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99915809T
Other languages
English (en)
Spanish (es)
Inventor
Veronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2300141T3 publication Critical patent/ES2300141T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
ES99915809T 1998-04-24 1999-04-22 Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson. Expired - Lifetime ES2300141T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR9805153 1998-04-24

Publications (1)

Publication Number Publication Date
ES2300141T3 true ES2300141T3 (es) 2008-06-01

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99915809T Expired - Lifetime ES2300141T3 (es) 1998-04-24 1999-04-22 Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson.

Country Status (22)

Country Link
US (1) US6387936B1 (no)
EP (1) EP1071422B1 (no)
JP (1) JP2002512963A (no)
KR (1) KR100597170B1 (no)
AT (1) ATE386520T1 (no)
AU (1) AU768069B2 (no)
CA (1) CA2329636C (no)
CY (1) CY1110448T1 (no)
CZ (1) CZ300825B6 (no)
DE (1) DE69938179T2 (no)
DK (1) DK1071422T3 (no)
ES (1) ES2300141T3 (no)
FR (1) FR2777781B1 (no)
HU (1) HU228902B1 (no)
IL (1) IL139164A (no)
NO (1) NO329032B1 (no)
PT (1) PT1071422E (no)
RU (1) RU2225204C2 (no)
SK (1) SK285531B6 (no)
UA (1) UA70319C2 (no)
WO (1) WO1999055336A1 (no)
ZA (1) ZA200005758B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1746985A4 (en) * 2004-05-21 2010-08-11 Univ Duke METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
PL1817006T3 (pl) * 2004-11-07 2013-03-29 F Timothy Guilford Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2363124B1 (en) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmaceutical compositions comprising droxidopa
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
DE69938179T2 (de) 2009-02-12
US6387936B1 (en) 2002-05-14
CZ20003908A3 (cs) 2001-02-14
ZA200005758B (en) 2002-01-17
PT1071422E (pt) 2008-05-05
JP2002512963A (ja) 2002-05-08
SK285531B6 (sk) 2007-03-01
CA2329636C (fr) 2009-09-08
CA2329636A1 (fr) 1999-11-04
FR2777781A1 (fr) 1999-10-29
NO20005290D0 (no) 2000-10-20
NO20005290L (no) 2000-10-20
CY1110448T1 (el) 2015-04-29
IL139164A0 (en) 2001-11-25
AU3425599A (en) 1999-11-16
DE69938179D1 (de) 2008-04-03
KR100597170B1 (ko) 2006-07-05
NO329032B1 (no) 2010-08-02
WO1999055336A1 (fr) 1999-11-04
ATE386520T1 (de) 2008-03-15
RU2225204C2 (ru) 2004-03-10
KR20010042960A (ko) 2001-05-25
DK1071422T3 (da) 2008-06-16
SK15882000A3 (sk) 2001-04-09
HUP0101645A2 (hu) 2001-09-28
EP1071422A1 (fr) 2001-01-31
HUP0101645A3 (en) 2002-10-28
AU768069B2 (en) 2003-12-04
FR2777781B1 (fr) 2004-04-09
UA70319C2 (en) 2004-10-15
EP1071422B1 (fr) 2008-02-20
HU228902B1 (en) 2013-06-28
IL139164A (en) 2005-12-18
CZ300825B6 (cs) 2009-08-19

Similar Documents

Publication Publication Date Title
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
US6387936B1 (en) Combinations of riluzole and levodopa for the treatment of Parkinson's disease
US4438119A (en) Method for alleviation of extrapyramidal motor disorders
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
CN105209036A (zh) 氧杂双环庚烷和氧杂双环庚烯的配制品
CN109475529B (zh) 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途
KR20140146217A (ko) 파킨슨병을 치료하는 방법
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
US6200607B1 (en) Pharmaceutical composition comprising at least tyrosine and an iron compound for treating parkinson's disease or depression
JPH08510990A (ja) グリシンｎｍｄａレセプター複合体の機能的アンタゴニストによる認識の改良方法
US20240366588A1 (en) Pharmaceutical solution for oral dosage
US20250049750A1 (en) Maltodextrin formulations
WO2001024792A1 (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
EP3556366B1 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
EP3366288A1 (en) Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon
ES2359910T3 (es) Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
JPS5824520A (ja) 精神病治療薬
JP6401028B2 (ja) 鯨筋肉抽出物からなる中長期記憶障害予防改善剤
CN119386006A (zh) 吲哚-3-甲醛在制备抗抑郁药物中的应用
TR2021022259A2 (tr) Imidurea Molekülü, Imidurea İzomer Molekül Formları veya Bunların Farmasotik Olarak Kabul Edilen Imidurea İzomer Molekül Formlarının Tuz Örneklerinin Asetilkolinesteraz İnhibitör Aktivitesi
MXPA00009524A (en) Riluzole and levodopa combinations for treating parkinson's disease
HUP0402593A2 (hu) Kariporidból és ramiprilből álló kombinációs készítmény és alkalmazása
HK1115813A (en) Treatment of depression and other affective disorders
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia